{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T23:56:40Z","timestamp":1773964600999,"version":"3.50.1"},"reference-count":155,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T00:00:00Z","timestamp":1580860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The activation of the PI3K\/AKT\/mTOR pathway is a main driver of cell growth, proliferation, survival, and chemoresistance of cancer cells, and, for this reason, represents an attractive target for developing targeted anti-cancer drugs. There are plenty of preclinical data sustaining the anti-tumor activity of dual PI3K\/mTOR inhibitors as single agents and in combination in lymphomas. Clinical responses, including complete remissions (especially in follicular lymphoma patients), are also observed in the very few clinical studies performed in patients that are affected by relapsed\/refractory lymphomas or chronic lymphocytic leukemia. In this review, we summarize the literature on dual PI3K\/mTOR inhibitors focusing on the lymphoma setting, presenting both the three compounds still in clinical development and those with a clinical program stopped or put on hold.<\/jats:p>","DOI":"10.3390\/ijms21031060","type":"journal-article","created":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T02:59:18Z","timestamp":1580957958000},"page":"1060","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Is There a Role for Dual PI3K\/mTOR Inhibitors for Patients Affected with Lymphoma?"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4394-7742","authenticated-orcid":false,"given":"Chiara","family":"Tarantelli","sequence":"first","affiliation":[{"name":"Institute of Oncology Research, Faculty of Biomedical Sciences, USI, 6500 Bellinzona, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0870-2376","authenticated-orcid":false,"given":"Antonio","family":"Lupia","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University \u201cMagna Gr\u00e6cia\u201d of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasios","family":"Stathis","sequence":"additional","affiliation":[{"name":"Oncology Institute of Southern Switzerland, 6500 Bellinzona, Switzerland"},{"name":"Faculty of Biomedical Sciences, USI, 6900 Lugano, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5637-8983","authenticated-orcid":false,"given":"Francesco","family":"Bertoni","sequence":"additional","affiliation":[{"name":"Institute of Oncology Research, Faculty of Biomedical Sciences, USI, 6500 Bellinzona, Switzerland"},{"name":"Oncology Institute of Southern Switzerland, 6500 Bellinzona, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,2,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ctrv.2017.07.005","article-title":"Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients","volume":"59","author":"Janku","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","article-title":"Targeting the PI3K pathway in cancer: Are we making headway?","volume":"15","author":"Janku","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K Pathway in Human Disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2174\/9781608051366113020007","article-title":"Recent Developments in Anticancer Agents Targeting PI3K, AKT and mTORC1\/2","volume":"2","author":"Brana","year":"2013","journal-title":"Top. Anti-Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12943-019-0954-x","article-title":"Targeting PI3K in cancer: Mechanisms and advances in clinical trials","volume":"18","author":"Yang","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_6","first-page":"49","article-title":"Development of drugs targeting the PI3K signalling pathway in leukemias and lymphomas","volume":"3","author":"Arcaro","year":"2015","journal-title":"EMJ"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrd2926","article-title":"Targeting the phosphoinositide 3-kinase pathway in cancer","volume":"8","author":"Liu","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc3860","article-title":"PI3K in cancer: Divergent roles of isoforms, modes of activation and therapeutic targeting","volume":"15","author":"Thorpe","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1002\/j.1460-2075.1995.tb07340.x","article-title":"A human phosphatidylinositol 3-kinase complex related to the yeast Vps34p-Vps15p protein sorting system","volume":"14","author":"Volinia","year":"1995","journal-title":"EMBO J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrm2882","article-title":"The emerging mechanisms of isoform-specific PI3K signalling","volume":"11","author":"Vanhaesebroeck","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.braindev.2008.04.006","article-title":"Hyperactivity, memory deficit and anxiety-related behaviors in mice lacking the p85\u03b1 subunit of phosphoinositide-3 kinase","volume":"31","author":"Tohda","year":"2009","journal-title":"Br. Dev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/npp.2013.20","article-title":"Memory of Conditioned Taste Aversion Is Erased by Inhibition of PI3K in the Insular Cortex","volume":"38","author":"Slouzkey","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.molmed.2007.04.002","article-title":"mTOR Complex1-S6K1 signaling: At the crossroads of obesity, diabetes and cancer","volume":"13","author":"Dann","year":"2007","journal-title":"Trends Mol. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1124\/pr.110.004051","article-title":"Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory\/autoimmune diseases and hematological malignancies","volume":"64","author":"Foster","year":"2012","journal-title":"Pharmacol. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1200\/JCO.2009.25.3641","article-title":"The PI3K pathway as drug target in human cancer","volume":"28","author":"Courtney","year":"2010","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1101\/gad.1212704","article-title":"Upstream and downstream of mTOR","volume":"18","author":"Hay","year":"2004","journal-title":"Genes Dev."},{"key":"ref_17","first-page":"3065","article-title":"Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer","volume":"118","author":"Carracedo","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR Signaling in Growth, Metabolism, and Disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1242\/jcs.1994.Supplement_18.18","article-title":"Specificity in recognition of phosphopeptides by src-homology 2 domains","volume":"1994","author":"Cantley","year":"1994","journal-title":"J. Cell Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.cmet.2007.03.006","article-title":"The GLUT4 glucose transporter","volume":"5","author":"Huang","year":"2007","journal-title":"Cell Metab."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-3-319-42118-6_3","article-title":"Metabolic Reprogramming by the PI3K-Akt-mTOR Pathway in Cancer","volume":"207","author":"Lien","year":"2016","journal-title":"Recent Results Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/emmm.201201953","article-title":"Long-term p110\u03b1 PI3K inactivation exerts a beneficial effect on metabolism","volume":"5","author":"Foukas","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cmet.2006.04.003","article-title":"Loss of class IA PI3K signaling in muscle leads to impaired muscle growth, insulin response, and hyperlipidemia","volume":"3","author":"Luo","year":"2006","journal-title":"Cell Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.ccell.2017.04.013","article-title":"A Pan-Cancer Proteogenomic Atlas of PI3K\/AKT\/mTOR Pathway Alterations","volume":"31","author":"Zhang","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of Cancer: The Next Generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ccell.2018.08.019","article-title":"Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers","volume":"34","author":"Yuan","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1001\/jamaoncol.2016.0891","article-title":"Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19784 Diverse Solid Tumors","volume":"2","author":"Millis","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1126\/science.1096502","article-title":"High frequency of mutations of the PIK3CA gene in human cancers","volume":"304","author":"Samuels","year":"2004","journal-title":"Science"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/ni.2771","article-title":"Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110delta result in T cell senescence and human immunodeficiency","volume":"15","author":"Lucas","year":"2014","journal-title":"Nat. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1073\/pnas.0510857103","article-title":"Cancer-specific mutations in PIK3CA are oncogenic in vivo","volume":"103","author":"Bader","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1073\/pnas.0408864102","article-title":"Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic","volume":"102","author":"Kang","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1073\/pnas.0510772103","article-title":"Oncogenic transformation induced by the p110\u03b2, -\u03b3, and -\u03b4 isoforms of class I phosphoinositide 3-kinase","volume":"103","author":"Kang","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"15547","DOI":"10.1073\/pnas.1009652107","article-title":"Cancer-derived mutations in the regulatory subunit p85\u03b1 of phosphoinositide 3-kinase function through the catalytic subunit p110\u03b1","volume":"107","author":"Sun","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nature05933","article-title":"A transforming mutation in the pleckstrin homology domain of AKT1 in cancer","volume":"448","author":"Carpten","year":"2007","journal-title":"Nature"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1038\/sj.leu.2404873","article-title":"PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma","volume":"21","author":"Abubaker","year":"2007","journal-title":"Leukemia"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/PDM.0b013e31815d0588","article-title":"Mutations of the PIK3CA gene in diffuse large B cell lymphoma","volume":"17","author":"Yu","year":"2008","journal-title":"Diagn. Mol. Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1182\/blood-2012-10-460832","article-title":"P110alpha-mediated constitutive PI3K signaling limits the efficacy of p110delta-selective inhibition in mantle cell lymphoma, particularly with multiple relapse","volume":"121","author":"Iyengar","year":"2013","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5724","DOI":"10.1158\/1078-0432.CCR-08-3215","article-title":"Phosphatidylinositol 3\u2019-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma","volume":"15","author":"Psyrri","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/10428190902803651","article-title":"Infrequent occurrence of PIK3CA mutations in chronic lymphocytic leukemia","volume":"50","author":"Marincevic","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1158\/1078-0432.CCR-11-2342","article-title":"Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia","volume":"18","author":"Brown","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"12420","DOI":"10.1073\/pnas.1305656110","article-title":"PTEN loss defines a PI3K\/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma","volume":"110","author":"Pfeifer","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.3109\/10428194.2010.502584","article-title":"PTEN tumor suppressor plays less prognostic role than P53 tumor suppressor in diffuse large B-cell lymphoma","volume":"51","author":"Liu","year":"2010","journal-title":"Leuk. Lymphoma"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Yahiaoui, O.I., Nunes, J.A., Castanier, C., Devillier, R., Broussais, F., Fabre, A.J., Naimi, D., Bouabdallah, R., Olive, D., and Xerri, L. (2014). Constitutive AKT activation in follicular lymphoma. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-565"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.3109\/10428194.2012.733880","article-title":"Low expression level of phosphatase and tensin homolog deleted on chromosome ten predicts poor prognosis in chronic lymphocytic leukemia","volume":"54","author":"Zou","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"13520","DOI":"10.1073\/pnas.0804295105","article-title":"Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways","volume":"105","author":"Lenz","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/ng.2468","article-title":"The genetic landscape of mutations in Burkitt lymphoma","volume":"44","author":"Love","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1182\/blood-2018-09-871418","article-title":"Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma","volume":"133","author":"Grande","year":"2019","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature11378","article-title":"Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics","volume":"490","author":"Schmitz","year":"2012","journal-title":"Nature"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1182\/blood.2019001880","article-title":"The whole-genome landscape of Burkitt lymphoma subtypes","volume":"134","author":"Panea","year":"2019","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/PPO.0b013e31826c5810","article-title":"Inhibitors of B-cell receptor signaling for patients with B-cell malignancies","volume":"18","author":"Choi","year":"2012","journal-title":"Cancer J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1073\/pnas.1205299110","article-title":"Genetic heterogeneity of diffuse large B-cell lymphoma","volume":"110","author":"Zhang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2016-10-747303","article-title":"Tonic B-cell receptor signaling in diffuse large B-cell lymphoma","volume":"130","author":"Havranek","year":"2017","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/43474","article-title":"NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling","volume":"401","author":"Romashkova","year":"1999","journal-title":"Nature"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1182\/blood-2006-04-016907","article-title":"Role of phosphatidylinositol 3\u2019-kinase\/AKT pathway in diffuse large B-cell lymphoma survival","volume":"108","author":"Uddin","year":"2006","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"9163","DOI":"10.18632\/oncotarget.7036","article-title":"Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma","volume":"7","author":"Ezell","year":"2016","journal-title":"Oncotarget"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Brenner, A.K., Andersson Tvedt, T.H., and Bruserud, \u00d8. (2016). The Complexity of Targeting PI3K-Akt-mTOR Signalling in Human Acute Myeloid Leukaemia: The Importance of Leukemic Cell Heterogeneity, Neighbouring Mesenchymal Stem Cells and Immunocompetent Cells. Molecules, 21.","DOI":"10.3390\/molecules21111512"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Conciatori, F., Bazzichetto, C., Falcone, I., Pilotto, S., Bria, E., Cognetti, F., Milella, M., and Ciuffreda, L. (2018). Role of mTOR Signaling in Tumor Microenvironment: An Overview. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19082453"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Beielstein, A.C., and Pallasch, C.P. (2019). Tumor Metabolism as a Regulator of Tumor-Host Interactions in the B-Cell Lymphoma Microenvironment-Fueling Progression and Novel Brakes for Therapy. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20174158"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3389\/fimmu.2018.00578","article-title":"mTOR at the Transmitting and Receiving Ends in Tumor Immunity","volume":"9","author":"Guri","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2217\/fon-2017-0588","article-title":"PI3K in cancer: Its structure, activation modes and role in shaping tumor microenvironment","volume":"14","author":"Liu","year":"2018","journal-title":"Future Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.semcancer.2017.04.015","article-title":"PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux","volume":"48","author":"Massi","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1158\/2159-8290.CD-16-0716","article-title":"Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy","volume":"6","author":"Okkenhaug","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1158\/1535-7163.MCT-10-0905","article-title":"Pushing the Envelope in the mTOR Pathway: The Second Generation of Inhibitors","volume":"10","author":"Vilar","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.18632\/oncotarget.659","article-title":"Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR cascade inhibitors: How mutations can result in therapy resistance and how to overcome resistance","volume":"3","author":"McCubrey","year":"2012","journal-title":"Oncotarget"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5528","DOI":"10.2174\/092986711798347298","article-title":"Dual inhibitors of PI3K\/mTOR or mTOR-selective inhibitors: Which way shall we go?","volume":"18","author":"Sabbah","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3389\/fphar.2016.00395","article-title":"Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives","volume":"7","author":"Ong","year":"2016","journal-title":"Front. Pharmacol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1039\/c2md20044a","article-title":"Small molecules targeting phosphoinositide 3-kinases","volume":"3","author":"Wu","year":"2012","journal-title":"MedChemComm"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"371","DOI":"10.18632\/oncotarget.477","article-title":"Two hits are better than one: Targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment","volume":"3","author":"Martelli","year":"2012","journal-title":"Oncotarget"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1002\/cbic.201200089","article-title":"The chemical biology of phosphoinositide 3-kinases","volume":"13","author":"Wymann","year":"2012","journal-title":"ChemBioChem"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"Rojo","year":"2006","journal-title":"Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1042\/BST20140034","article-title":"Anticipating mechanisms of resistance to PI3K inhibition in breast cancer: A challenge in the era of precision medicine","volume":"42","author":"Leroy","year":"2014","journal-title":"Biochem. Soc. Trans."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"8022","DOI":"10.1158\/0008-5472.CAN-08-1385","article-title":"NVP-BEZ235, a dual PI3K\/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations","volume":"68","author":"Serra","year":"2008","journal-title":"Cancer Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1158\/2159-8290.CD-11-0249","article-title":"PI3Kdelta inhibitors in cancer: Rationale and serendipity merge in the clinic","volume":"1","author":"Fruman","year":"2011","journal-title":"Cancer Discov."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/1078-0432.CCR-12-1060","article-title":"PAK1 mediates resistance to PI3K inhibition in lymphomas","volume":"19","author":"Walsh","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1158\/1078-0432.CCR-17-1041","article-title":"PQR309 Is a Novel Dual PI3K\/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy","volume":"24","author":"Tarantelli","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.canlet.2012.11.013","article-title":"Concurrent inhibition of PI3-kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1","volume":"339","author":"Zang","year":"2013","journal-title":"Cancer Lett."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1158\/1535-7163.MCT-11-0446","article-title":"GDC-0980 is a novel class I PI3K\/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway","volume":"10","author":"Wallin","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"5893","DOI":"10.1182\/blood.V128.22.5893.5893","article-title":"A Dose-Escalation (DE) Study with Expansion Evaluating Safety, Pharmacokinetics and Efficacy of the Novel, Balanced PI3K\/mTOR Inhibitor PQR309 in Patients with Relapsed or Refractory Lymphoma","volume":"128","author":"Collins","year":"2016","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.3109\/10428194.2014.974040","article-title":"Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase\/mammalian target of rapamycin inhibitor: A phase 1 expansion cohort in patients with relapsed or refractory lymphoma","volume":"56","author":"Papadopoulos","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1016\/S2352-3026(18)30030-9","article-title":"Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: An open-label, phase 2 trial","volume":"5","author":"Brown","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1016\/j.ejca.2012.06.027","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K\/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies","volume":"48","author":"Mahadevan","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1182\/blood.V118.21.2720.2720","article-title":"SF1126, a Pan-PI3K Inhibitor Has Superior Preclinical Activity to CAL-101 a PI3K Delta-Specific Inhibitor in Aggressive B-Cell Non-Hodgkin\u2019s Lymphoma","volume":"118","author":"Mahadevan","year":"2011","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"D945","DOI":"10.1093\/nar\/gkw1074","article-title":"The ChEMBL database in 2017","volume":"45","author":"Gaulton","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1021\/acs.jcim.5b00559","article-title":"ZINC 15--Ligand Discovery for Everyone","volume":"55","author":"Sterling","year":"2015","journal-title":"J. Chem. Inf. Model."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"D1102","DOI":"10.1093\/nar\/gky1033","article-title":"PubChem 2019 update: Improved access to chemical data","volume":"47","author":"Kim","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: A major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1158\/1078-0432.CCR-18-3049","article-title":"The Dual PI3K\/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases","volume":"25","author":"Ippen","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1021\/acsmedchemlett.6b00005","article-title":"Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR","volume":"7","author":"Heffron","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1200\/JCO.2016.34.15_suppl.2012","article-title":"A first-in-human phase 1 study to evaluate the brain-penetrant PI3K\/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma","volume":"34","author":"Wen","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1021\/jm901830p","article-title":"Bis(morpholino-1,3,5-triazine) derivatives: Potent adenosine 5\u2019-triphosphate competitive phosphatidylinositol-3-kinase\/mammalian target of rapamycin inhibitors: Discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor","volume":"53","author":"Venkatesan","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1158\/1078-0432.CCR-10-1694","article-title":"Antitumor efficacy of PKI-587, a highly potent dual PI3K\/mTOR kinase inhibitor","volume":"17","author":"Mallon","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.canlet.2017.01.035","article-title":"The dual specificity PI3K\/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL)","volume":"392","author":"Gazi","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood-2016-05-707653","article-title":"Potent efficacy of combined PI3K\/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia","volume":"129","author":"Tasian","year":"2017","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1038\/onc.2016.41","article-title":"Aberrant activation of the PI3K\/mTOR pathway promotes resistance to sorafenib in AML","volume":"35","author":"Lindblad","year":"2016","journal-title":"Oncogene"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13148-018-0516-x","article-title":"Acute leukemia cells resistant to PI3K\/mTOR inhibition display upregulation of P2RY14 expression","volume":"10","author":"Shah","year":"2018","journal-title":"Clin. Epigenet."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1158\/1078-0432.CCR-14-1306","article-title":"First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer","volume":"21","author":"Shapiro","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"7524","DOI":"10.1021\/acs.jmedchem.7b00930","article-title":"5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K\/mTOR Inhibitor as Clinical Candidate in Oncology","volume":"60","author":"Beaufils","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1158\/1535-7163.MCT-13-0709","article-title":"Characterization of the activity of the PI3K\/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway","volume":"13","author":"Yu","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e256","DOI":"10.3324\/haematol.2018.207027","article-title":"New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease","volume":"104","author":"Aresu","year":"2019","journal-title":"Haematologica"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1073\/pnas.012605099","article-title":"Phosphoinositide 3-kinase and Bruton\u2019s tyrosine kinase regulate overlapping sets of genes in B lymphocytes","volume":"99","author":"Fruman","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Chen, L., Ouyang, J., Wienand, K., Bojarczuk, K., Hao, Y., Chapuy, B., Neuberg, D., Juszczynski, P., Lawton, L.N., and Rodig, S.J. (2019). CXCR4 upregulation is an indicator of sensitivity to B-cell receptor\/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas. Haematologica.","DOI":"10.3324\/haematol.2019.216218"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejca.2018.03.012","article-title":"First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1\/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67\/13)","volume":"96","author":"Wicki","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/leu.2015.241","article-title":"The pan phosphoinositide 3-kinase\/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib\/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells","volume":"30","author":"Thijssen","year":"2016","journal-title":"Leukemia"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/bjh.14181","article-title":"Phase Ib trial of the PI3K\/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies","volume":"175","author":"Awan","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1158\/1078-0432.CCR-13-2403","article-title":"Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K\/mTOR inhibitor in patients with advanced solid tumors","volume":"20","author":"Papadopoulos","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s10637-017-0467-7","article-title":"A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors","volume":"36","author":"Mehnert","year":"2018","journal-title":"Investig. New Drugs"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1158\/0008-5472.CAN-07-0669","article-title":"A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity","volume":"68","author":"Garlich","year":"2008","journal-title":"Cancer Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1021\/jm301522m","article-title":"Synthesis and cancer stem cell-based activity of substituted 5-morpholino-7H-thieno[3,2-b]pyran-7-ones designed as next generation PI3K inhibitors","volume":"56","author":"Morales","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1021\/cb400789e","article-title":"The commonly used PI3-kinase probe LY294002 is an inhibitor of BET bromodomains","volume":"9","author":"Dittmann","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.4172\/1948-5956.1000143","article-title":"SF1126, a Pan-PI3K Inhibitor has Potent Pre-Clinical Activity in Aggressive B-Cell Non-Hodgkin Lymphomas by Inducing Cell Cycle Arrest and Apoptosis","volume":"4","author":"Qi","year":"2012","journal-title":"J. Cancer Sci. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s00280-013-2078-0","article-title":"An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo","volume":"71","author":"De","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_112","unstructured":"Broggini, M., and Caiola, E. (2015, May 24). ESMO E-Learning: PI3K\/Akt\/mTOR Pathway. Available online: https:\/\/oncologypro.esmo.org\/Education-Library\/ESMO-E-Learning-and-V-Learning\/PI3K-Akt-mTOR-Pathway."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1158\/1078-0432.CCR-15-1665","article-title":"First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies","volume":"22","author":"Munster","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00280-018-3610-z","article-title":"Phase 1\/1b dose escalation and expansion study of BEZ235, a dual PI3K\/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer","volume":"82","author":"Rodon","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ygyno.2016.04.019","article-title":"A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer","volume":"142","author":"Birrer","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1093\/annonc\/mds011","article-title":"Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors","volume":"23","author":"Markman","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00280-019-03883-6","article-title":"Phase I study of BGT226, a pan-PI3K and mTOR inhibitor, in Japanese patients with advanced solid cancers","volume":"84","author":"Minami","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1634\/theoncologist.2016-0145","article-title":"A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients with Advanced Renal Cell Carcinoma","volume":"21","author":"Carlo","year":"2016","journal-title":"Oncologist"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"iv153","DOI":"10.1093\/annonc\/mdu331.20","article-title":"460PPHASE I CLINICAL TRIAL OF DS-7423, AN ORAL PI3K\/MTOR DUAL INHIBITOR, IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS","volume":"25","author":"Yokota","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1158\/1078-0432.CCR-15-2225","article-title":"Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors","volume":"22","author":"Dolly","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s10637-013-0062-5","article-title":"Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer","volume":"32","author":"Britten","year":"2014","journal-title":"Investig. New Drugs"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s10637-015-0218-6","article-title":"A phase 1 study of the sachet formulation of the oral dual PI3K\/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors","volume":"33","author":"Bendell","year":"2015","journal-title":"Investig. New Drugs"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"B153","DOI":"10.1158\/1535-7163.TARG-11-B153","article-title":"Abstract B153: A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamic (PD) activity of the dual PI3K\/mTOR inhibitor GDC-0980 administered once weekly (QW)","volume":"10","author":"Hollebecque","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00280-018-3725-2","article-title":"A phase I study of single-agent BEZ235 special delivery system sachet in Japanese patients with advanced solid tumors","volume":"83","author":"Toyoda","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Vergaro, V., Civallero, M., Citti, C., Cosenza, M., Baldassarre, F., Cannazza, G., Pozzi, S., Sacchi, S., Fanizzi, F.P., and Ciccarella, G. (2018). Cell-Penetrating CaCO(3) Nanocrystals for Improved Transport of NVP-BEZ235 across Membrane Barrier in T-Cell Lymphoma. Cancers, 10.","DOI":"10.3390\/cancers10020031"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1080\/10717544.2018.1444683","article-title":"Antitumor efficacy of liposome-encapsulated NVP-BEZ 235 in combination with irreversible electroporation","volume":"25","author":"Tian","year":"2018","journal-title":"Drug Deliv."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s11523-017-0530-5","article-title":"A Multi-Arm Phase I Study of the PI3K\/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer","volume":"12","author":"Wainberg","year":"2017","journal-title":"Target. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10549-015-3615-9","article-title":"Phase I\/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor","volume":"154","author":"Blackwell","year":"2015","journal-title":"Br. Cancer Res. Treat."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejca.2017.01.024","article-title":"Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer","volume":"76","author":"Massard","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11523-017-0482-9","article-title":"A Phase Ib Study of the Dual PI3K\/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies","volume":"12","author":"Moorthy","year":"2017","journal-title":"Target. Oncol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"503-e43","DOI":"10.1634\/theoncologist.2016-0432","article-title":"A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K\/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer","volume":"22","author":"Wei","year":"2017","journal-title":"Oncologist"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1007\/s10637-016-0377-0","article-title":"A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K\/mTOR inhibitor GSK2126458 in patients with advanced solid tumors","volume":"34","author":"Bedard","year":"2016","journal-title":"Investig. New Drugs"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/JTO.0000000000000088","article-title":"Phase I safety and pharmacokinetic study of the PI3K\/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors","volume":"9","author":"Janne","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1517\/13543784.2012.719871","article-title":"NVP-BEZ235 alone and in combination in mantle cell lymphoma: An effective therapeutic strategy","volume":"21","author":"Civallero","year":"2012","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13045-016-0303-0","article-title":"Synergistic effect of oridonin and a PI3K\/mTOR inhibitor on the non-germinal center B cell-like subtype of diffuse large B cell lymphoma","volume":"9","author":"Qing","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3892\/ijo.2015.3231","article-title":"PF-04691502, a dual PI3K\/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin lymphomas","volume":"48","author":"Chen","year":"2016","journal-title":"Int. J. Oncol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1073\/pnas.1524668113","article-title":"Augmented efficacy of brentuximab vedotin combined with ruxolitinib and\/or Navitoclax in a murine model of human Hodgkin\u2019s lymphoma","volume":"113","author":"Ju","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"870918","DOI":"10.1155\/2015\/870918","article-title":"Activity of BKM120 and BEZ235 against Lymphoma Cells","volume":"2015","author":"Civallero","year":"2015","journal-title":"BioMed Res. Int."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"e1593","DOI":"10.1038\/cddis.2014.525","article-title":"MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies","volume":"6","author":"Choudhary","year":"2015","journal-title":"Cell. Death Dis."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"35202","DOI":"10.18632\/oncotarget.6051","article-title":"MCL-1-independent mechanisms of synergy between dual PI3K\/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma","volume":"6","author":"Lee","year":"2015","journal-title":"Oncotarget"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"5378","DOI":"10.1182\/blood-2018-99-113997","article-title":"GSK458 Is a Novel Dual PI3K\/mTOR Inhibitor with Preclinical Antitumor Activity in T Cell Lymphomas as a Single Agent and in Combination Therapy","volume":"132","author":"Gu","year":"2018","journal-title":"Blood"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1080\/15384047.2015.1018495","article-title":"Co-targeting of Akt and Myc inhibits viability of lymphoma cells from Lck-Dlx5 mice","volume":"16","author":"Tan","year":"2015","journal-title":"Cancer Biol. Ther."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1073\/pnas.1311846111","article-title":"High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells","volume":"111","author":"Guha","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.leukres.2012.02.010","article-title":"The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells","volume":"36","author":"Kim","year":"2012","journal-title":"Leuk. Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.1158\/1078-0432.CCR-14-0034","article-title":"PI3K\/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo","volume":"20","author":"Rahmani","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13046-016-0327-x","article-title":"Low dose of lenalidmide and PI3K\/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma","volume":"35","author":"Jin","year":"2016","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1182\/blood.V118.21.4965.4965","article-title":"NVP-BEZ235, A Dual Inhibitor of Phosphoinositol-3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), Is a Potent Inhibitor of Lymphoma Cell Growth and Survival","volume":"118","author":"Buglio","year":"2011","journal-title":"Blood"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3109\/10428194.2014.917639","article-title":"Dual inhibition of phosphatidylinositol 3-kinase\/mammalian target of rapamycin and mitogen activated protein kinase pathways in non-Hodgkin lymphoma","volume":"56","author":"Anders","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1038\/leu.2010.154","article-title":"The dual PI3K\/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma","volume":"24","author":"Bhende","year":"2010","journal-title":"Leukemia"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.1182\/blood.V128.22.5376.5376","article-title":"Omipalisib (GSK458), a Novel Pan-PI3K\/mTOR Inhibitor, Exhibits In Vitro Anti-Lymphoma Activity in Chemotherapy-Sensitive and -Resistant Models of Burkitt Lymphoma","volume":"128","author":"Ippolito","year":"2016","journal-title":"Blood"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s40265-019-01163-4","article-title":"Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies","volume":"79","author":"Yalniz","year":"2019","journal-title":"Drugs"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1182\/blood.V122.21.817.817","article-title":"Inhibition of PI3K\/mTOR by BEZ235 Dramatically Potentiates Panobinostat-Induced Lethality in Diffuse Large B-Cell Lymphoma Through Multiple Mechanisms","volume":"122","author":"Aust","year":"2013","journal-title":"Blood"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood-2013-04-495366","article-title":"AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia","volume":"123","author":"Keeton","year":"2014","journal-title":"Blood"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2019-123742","article-title":"Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines","volume":"134","author":"Schuster","year":"2019","journal-title":"Blood"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ctrv.2018.04.002","article-title":"Bispecific antibodies in haematological malignancies","volume":"65","author":"Viardot","year":"2018","journal-title":"Cancer Treat. Rev."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/3\/1060\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T08:55:03Z","timestamp":1760172903000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/3\/1060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,5]]},"references-count":155,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["ijms21031060"],"URL":"https:\/\/doi.org\/10.3390\/ijms21031060","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,5]]}}}